Thought Leadership
Gene Editing Biotechs Face New Uncertainty After CRISPR Patent Ruling
March 2, 2022
Jonathan Gardner
BioPharma Dive

Axinn partner David Silverstein was quoted in the BioPharma Dive article, "Gene Editing Biotechs Face New Uncertainty After CRISPR Patent Ruling."

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.